Impaired phagocytosis of apoptotic cell material in serologically active clinically quiescent patients with systemic lupus erythematosis

International Journal of Rheumatic Diseases

Volumn 19, Issue 12, 2016, Pages 1310-1316

  Huang, Wen Nan ^a   Tso, Tim K ^b   Wu, Hsiao Chih ^b   Yang, Hsiu Fen ^b   Tsay, Gregory J ^c,d  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL CHIAYI UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

interleukin; macrophage; monocyte; phagocytosis; systemic lupus erythematosus

Indexed keywords

ADULT; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL PHAGOCYTOSIS; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HUMAN; MACROPHAGE FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOCYTE; NEUTROPHIL; RECURRENT DISEASE; SEROLOGICALLY ACTIVE CLINICALLY QUIESCENT SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS; YOUNG ADULT; BLOOD; CASE CONTROL STUDY; CELL CULTURE; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MACROPHAGE; PATHOLOGY; PHAGOCYTOSIS; SEROLOGY; SERUM-FREE MEDIUM;

ANTINUCLEAR ANTIBODY; BIOLOGICAL MARKER; C3 PROTEIN, HUMAN; CHEMOKINE; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CYTOKINE; SERUM-FREE MEDIUM;

ADULT; ANTIBODIES, ANTINUCLEAR; APOPTOSIS; BIOMARKERS; CASE-CONTROL STUDIES; CELLS, CULTURED; CHEMOKINES; COMPLEMENT C3; COMPLEMENT C4; CULTURE MEDIA, SERUM-FREE; CYTOKINES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MACROPHAGES; NEUTROPHILS; PHAGOCYTOSIS; SEROLOGIC TESTS;

EID: 84952705426     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/1756-185X.12826     Document Type: Article

References (33)

1. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40, 1725.
2. Zonana-Nacach A, Salas M, Sanchez ML, Camargo-Coronel A, Bravo-Gatica C, Mintz G (1995) Measurement of clinical activity of systemic lupus erythematosus and laboratory abnormalities: a 12-month prospective study. J Rheumatol 22, 45–9.
3. Witte T, Hartung K, Matthias T et al. (1998) Association of IgA anti-dsDNA antibodies with vasculitis and disease activity in systemic lupus erythematosus. Rheumatol Int 18, 63–9.
4. Ho A, Magder LS, Barr SG, Petri M (2001) Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 44, 2342–9.
5. Riboldi P, Gerosa M, Moroni G et al. (2005) Anti-DNA antibodies: a diagnostic and prognostic tool for systemic lupus erythematosus? Autoimmunity 38, 39–45.
6. Mollnes TE, Haga HJ, Brun JG et al. (1999) Complement activation in patients with systemic lupus erythematosus without nephritis. Rheumatology 38, 933–40.
7. Gladman DD, Urowitz MB, Keystone EC (1979) Serologically active clinically quiescent systemic lupus erythematosus: a discordance between clinical and serologic features. Am J Med 66, 210–5.
8. Emlen W, Niebur J, Kadera R (1994) Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 152, 3685–92.
9. Lorenz HM, Grunke M, Hieronymus T et al. (1997) In vitro apoptosis and expression of apoptosis-related molecules in lymphocytes from patients with systemic lupus erythematosus and other autoimmune diseases. Arthritis Rheum 40, 306–17.
10. Perniok A, Wedekind F, Herrmann M, Specker C, Schneider M (1998) High levels of circulating early apoptotic peripheral blood mononuclear cells in systemic lupus erythematosus. Lupus 7, 113–8.
11. Casciola-Rosen LA, Anhalt GJ, Rosen A (1995) DNA-dependent protein kinase is one of a subset of autoantigens specifically cleaved early during apoptosis. J Exp Med 182, 1625–34.
12. Savill J, Dransfield I, Gregory C, Haslett C (2002) A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol 2, 965–75.
13. Casciola-Rosen LA, Anhalt G, Rosen A (1994) Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 179, 1317–30.
14. Eguchi K (2001) Apoptosis in autoimmune diseases. Intern Med 40, 275–84.
15. Miranda ME, Tseng CE, Rashbaum W et al. (1998) Accessibility of SSA/Ro and SSB/La antigens to maternal autoantibodies in apoptotic human fetal cardiac myocytes. J Immunol 161, 5061–9.
16. Pitidhammabhorn D, Kantachuvesiri S, Totemchokchyakarn K, Kitiyanant Y, Ubol S (2006) Partial construction of apoptotic pathway in PBMC obtained from active SLE patients and the significance of plasma TNF-alpha on this pathway. Clin Rheumatol 25, 705–14.
17. Herrmann M, Voll RE, Kalden JR (2000) Etiopathogenesis of systemic lupus erythematosus. Immunol Today 21, 424–6.
18. Richardson BC, Strahler JR, Pivirotto TS et al. (1992) Phenotypic and functional similarities between 5-azacytidine-treated T cells and a T cell subset in patients with active systemic lupus erythematosus. Arthritis Rheum 35, 647–62.
19. Kaplan MJ, Lewis EE, Shelden EA et al. (2002) The apoptotic ligands TRAIL, TWEAK, and Fas ligand mediate monocyte death induced by autologous lupus T cells. J Immunol 169, 6020–9.
20. Bengtsson AA, Sturfelt G, Gullstrand B, Truedsson L (2004) Induction of apoptosis in monocytes and lymphocytes by serum from patients with systemic lupus erythematosus - an additional mechanism to increased autoantigen load? Clin Exp Immunol 135, 535–43.
21. Ren Y, Tang J, Mok MY, Chan AW, Wu A, Lau CS (2003) Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus. Arthritis Rheum 48, 2888–97.
22. Steiman AJ, Gladman DD, Ibanez D, Urowitz MB (2010) Prolonged serologically active clinically quiescent systemic lupus erythematosus: frequency and outcome. J Rheumatol 37, 1822–7.
23. Ceccarelli F, Perricone C, Massaro L et al. (2015) Assessment of disease activity in Systemic Lupus Erythematosus: lights and shadows. Autoimmun Rev 14, 601–8.
24. Walz LeBlanc BA, Gladman DD, Urowitz MB (1994) Serologically active clinically quiescent systemic lupus erythematosus — predictors of clinical flares. J Rheumatol 21, 2239–41.
25. Ng KP, Manson JJ, Rahman A, Isenberg DA (2006) Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus. Arthritis Care Res 55, 900–4.
26. Gladman DD, Hirani N, Ibañez D, Urowitz MB (2003) Clinically active serologically quiescent systemic lupus erythematosus. J Rheumatol 30, 1960–2.
27. Courtney PA, Crockard AD, Williamson K, Irvine AE, Kennedy RJ, Bell AL (1999) Increased apoptotic peripheral blood neutrophils in systemic lupus erythematosus: relations with disease activity, antibodies to double stranded DNA, and neutropenia. Ann Rheum Dis 58, 309–14.
28. Bengtsson AA, Gullstrand B, Truedsson L, Sturfelt G (2008) SLE serum induces classical caspase-dependent apoptosis independent of death receptors. Clin Immun 126, 57–66.
29. Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden JR (1998) Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 41, 1241–50.
30. Tas SW, Quartier P, Botto M, Fossati-Jimack L (2006) Macrophages from patients with SLE and rheumatoid arthritis have defective adhesion in vitro, while only SLE macrophages have impaired uptake of apoptotic cells. Ann Rheum Dis 65, 216–21.
31. Tanaka T, Terada M, Ariyoshi K, Morimoto K (2010) Monocyte chemoattractant protein-1/CC chemokine ligand 2 enhances apoptotic cell removal by macrophages through Rac1 activation. Biochem Biophys Res Commun 399, 677–82.
32. Xia M, Sui Z (2009) Recent developments in CCR2 antagonists. Expert Opin Ther Pat 19, 295–303.
33. Shah D, Wanchu A, Bhatnagar A (2011) Interaction between oxidative stress and chemokines: possible pathogenic role in systemic lupus erythematosus and rheumatoid arthritis. Immunobiology 216, 1010–7.